WT1 and mesothelioma: However, if the immunopeptidome presented by MHC-I can be altered by the use of selective immunoproteasome inhibitors such as ONX-0914, the type and amount of neoantigen-derived epitopes other than WT1 may be altered and the immunogenicity of mesothelioma cells may be enhanced.